Background: Despite its prevalence and the significance of early diagnosis, non-alcoholic fatty liver disease (NAFLD), one of the most prevalent liver diseases globally and frequently linked to elements of metabolic syndrome, lacks robustly validated biomarkers for diagnosis, prognosis, and tracking of disease progression in response to a particular treatment.
Objective: The aim of this study was to catalogue the metabolites from metabolomics data reported by different studies till date, and to find few majorly dysregulated metabolites that can potentially be used as progressive biomarkers of NAFLD in future.
Methods: The clinical data published during last 13 years was investigated and further curated from established databases of MEDLINE, EMBASE and PUBMED on NAFLD.